Noble Financial Issues Negative Outlook for UNCY Earnings

Key Points

• Noble Financial sharply cut its Q1 2027 EPS estimate for Unicycive Therapeutics to a loss of $0.14 from a prior estimate of $0.64. The broader analyst consensus calls for a full-year loss of $1.16 per share.
• Despite the earnings downgrade, analysts maintain a generally positive view, with five Buy ratings, one Hold, and one Sell, producing a “Moderate Buy” consensus and an $18.25 average price target.
• UNCY shares opened at $3.89, near the lower end of their 12-month range of $3.35 to $8.74. The company’s lead drug candidate, oxylanthanum carbonate, has an FDA action date of March 25, 2027, while pending securities litigation adds risk.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Noble Financial dropped their Q1 2027 earnings estimates for Unicycive Therapeutics in a report released on Thursday, October 22nd. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings per share of ($0.14) for the quarter, down from their prior estimate of $0.64. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($1.16) per share. Noble Financial also issued estimates for Unicycive Therapeutics' Q2 2027 earnings at $0.49 EPS, Q3 2027 earnings at $0.67 EPS, Q4 2027 earnings at $0.79 EPS and FY2027 earnings at $1.81 EPS.

A number of other brokerages have also weighed in on UNCY. Zacks Research raised shares of Unicycive Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 19th. Guggenheim reissued a "buy" rating and set a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 13th. Wall Street Zen raised shares of Unicycive Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. HC Wainwright dropped their price objective on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, September 29th. Finally, B. Riley Financial reiterated a "buy" rating and set a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $18.25.

Unicycive Therapeutics Stock Performance

Shares of UNCY opened at $3.89 on Monday. The firm has a market cap of $108.34 million, a P/E ratio of -2.22 and a beta of 1.83. The stock's 50 day moving average is $4.72 and its two-hundred day moving average is $5.95. Unicycive Therapeutics has a 12 month low of $3.35 and a 12 month high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.41.

Institutional Investors Weigh In On Unicycive Therapeutics

Several institutional investors have recently modified their holdings of UNCY. Seven Fleet Capital Management LP lifted its holdings in Unicycive Therapeutics by 85.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company's stock worth $521,000 after buying an additional 47,700 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Unicycive Therapeutics during the 2nd quarter worth about $248,000. Bank of America Corp DE lifted its stake in Unicycive Therapeutics by 19,327.6% during the first quarter. Bank of America Corp DE now owns 29,530 shares of the company's stock worth $194,000 after purchasing an additional 29,378 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Unicycive Therapeutics in the first quarter valued at approximately $161,000. Finally, Dimensional Fund Advisors LP acquired a new position in Unicycive Therapeutics in the first quarter valued at approximately $940,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: The FDA accepted Unicycive’s resubmitted New Drug Application for oxylanthanum carbonate, a potential phosphate binder for patients with chronic kidney disease on dialysis. The resubmission includes Chemistry, Manufacturing, and Controls data from a new drug-product manufacturing vendor. The FDA assigned a March 25, 2027 PDUFA action date, providing a defined regulatory catalyst, although acceptance does not guarantee approval. FDA acceptance and PDUFA date article
• Positive Sentiment: The average analyst price target reportedly increased 12.32% to $32.54, suggesting substantial potential upside relative to recent trading levels. However, price targets can change quickly and may reflect limited analyst coverage for the clinical-stage biotechnology company. Analyst price target article
• Neutral Sentiment: Multiple law firms reminded investors of a November 2, 2026 lead-plaintiff deadline in a pending securities class action covering purchases from December 29, 2025 through June 29, 2026. The notices largely repeat the same litigation information rather than represent new operating developments. Class-action deadline notice
• Negative Sentiment: The lawsuit alleges Unicycive failed to disclose that it had not inspected or audited its third-party manufacturer’s facility for current Good Manufacturing Practice compliance before an earlier NDA resubmission. Plaintiffs claim this exposed investors to another Complete Response Letter and contributed to a reported 39.1% stock decline. The allegations have not been proven, but the litigation creates legal costs, reputational risk, and uncertainty around the company’s manufacturing readiness. Securities lawsuit allegations

About Unicycive Therapeutics

Unicycive Therapeutics, Inc NASDAQ: UNCY is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company's primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis.

Unicycive's lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.